Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma
Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma.
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
Fierce Pharma1d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mn
Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...
Finely tuned large language models can extract PD-L1 biomarker details from electronic health records
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from an electronic health record (EHR).
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
The American Journal of Managed Care7d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
Medscape6d
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
Targeted Oncology7d
Understanding the Use of Nivolumab in the Current Upper GI Landscape
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...